ABVC BioPharma, Inc.’s (OTCMKTS:ABVC) Lock-Up Period To End on January 31st

ABVC BioPharma’s (OTCMKTS:ABVC) lock-up period will expire on Monday, January 31st. ABVC BioPharma had issued 1,100,000 shares in its IPO on August 3rd. The total size of the offering was $6,875,000 based on an initial share price of $6.25. After the end of ABVC BioPharma’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

OTCMKTS:ABVC opened at $2.72 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.05 and a current ratio of 2.07. The company has a fifty day moving average of $3.35 and a two-hundred day moving average of $3.30. ABVC BioPharma has a fifty-two week low of $1.95 and a fifty-two week high of $11.69.

ABVC BioPharma (OTCMKTS:ABVC) last announced its quarterly earnings data on Monday, November 15th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.03). ABVC BioPharma had a negative net margin of 2,145.77% and a negative return on equity of 318.25%. The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.14 million. As a group, sell-side analysts anticipate that ABVC BioPharma will post -0.23 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Credit Suisse AG acquired a new stake in ABVC BioPharma in the third quarter valued at approximately $27,000. Squarepoint Ops LLC purchased a new stake in ABVC BioPharma in the third quarter valued at $44,000. Finally, Geode Capital Management LLC purchased a new stake in ABVC BioPharma in the third quarter valued at $115,000. 0.79% of the stock is currently owned by institutional investors and hedge funds.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm’s products pipeline include ABV-1501, which is a combination therapy for triple negative breast cancer (TNBC); ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine; ABV-1505 for treating attention deficit hyperactivity disorder (ADHD); ABV-1702 is to treat myelodysplastic syndromes (MDS); ABV-1703 for Pancreatic Cancer; ABV-1601 for treating depression in cancer patients; ABV-1701 is a vitreous substitute for vitrectomy; ABV-2001; and ABV-2002.

Recommended Story: Initial Coin Offering (ICO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in ABVC BioPharma right now?

Before you consider ABVC BioPharma, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ABVC BioPharma wasn’t on the list.

While ABVC BioPharma currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Source link